Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

IACS-13909 is an allosteric inhibitor of Src homology region 2 domain-containing phosphatase 2 (SHP-2; IC50 = 11 nM).1 It binds wild-type SHP-2 and SHP-2 containing a constitutively activating glutamate-to-lysine substitution at position 76 (SHP-2E76K; Kds = 49 and 211 nM, respectively). IACS-13909 decreases the levels of phosphorylated ERK in KYSE-520 esophageal squamous cell carcinoma cells (IC50 = 47 nM) but also inhibits human-ether-a-go-go (hERG) channels (IC50 = 180 nM in whole-cell patch-clamp assays using CHO cells). It decreases tumor volume without affecting body weight in an EGFR-overexpressing KYSE-520 mouse xenograft model when administered at a dose of 70 mg/kg per day.2 IACS-13909 (70 mg/kg per day) induces sustained reduction in tumor volume after dosing cessation in a non-small cell lung cancer (NSCLC) mouse xenograft model using H1975 cells expressing drug-resistant EGFRL858R/T790M/C797S.
WARNING This product is not for human or veterinary use.
1. Discovery of 6-
2. Allosteric SHP2 inhibitor, IACS-